Small molecule-based inhibitors for treatment of tick-borne encephalitis virus infection: Nucleoside analogs and nonnucleoside antivirals
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60077344%3A_____%2F22%3A00569226" target="_blank" >RIV/60077344:_____/22:00569226 - isvavai.cz</a>
Result on the web
<a href="https://www.sciencedirect.com/science/article/abs/pii/S0065774322000033?pes=vor" target="_blank" >https://www.sciencedirect.com/science/article/abs/pii/S0065774322000033?pes=vor</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/bs.armc.2022.08.003" target="_blank" >10.1016/bs.armc.2022.08.003</a>
Alternative languages
Result language
angličtina
Original language name
Small molecule-based inhibitors for treatment of tick-borne encephalitis virus infection: Nucleoside analogs and nonnucleoside antivirals
Original language description
Tick-borne encephalitis (TBE) is one of the most serious neurological infections in Europe and Northeastern Asia. The causative agent of TBE is the tick-borne encephalitis virus (TBEV). Although several effective vaccines are legislated to prevent TBE, there are currently no approved treatments/anti-TBEV drugs other than supportive measures. Therefore, there is an urgent medical need for the development of novel, specific, and effective antivirals to treat patients with TBEV infection. This report summarizes the available information on antiviral research on small molecule-based inhibitors of TBEV replication. The main focus is on the description of nucleoside analogs, a leading group of antiviral compounds with the highest anti-TBEV potency. Various sugar/nucleobase modifications of the nucleoside scaffold that have been made to maximize the antiviral activity and decrease the cytotoxicity of the compounds are discussed. Emphasis is also placed on elucidating the mechanism of action of the inhibitors studied and their relationship to the development of antiviral resistance. Moreover, a brief overview of nonnucleoside inhibitors, natural compounds, repurposed drugs, and synthetic broad-spectrum antivirals is also part of this chapter. The review shows that specific therapies based on small-molecule inhibitors, in combination with effective vaccination strategies, could be effective prophylactic and curative tools to control TBEV infections in humans.
Czech name
—
Czech description
—
Classification
Type
C - Chapter in a specialist book
CEP classification
—
OECD FORD branch
10606 - Microbiology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Book/collection name
Annual Reports in Medicinal Chemistry
ISBN
9780323988933
Number of pages of the result
38
Pages from-to
"Roč. 58 (2022)"
Number of pages of the book
256
Publisher name
Springer
Place of publication
Cham
UT code for WoS chapter
—